Indivior Pharmaceuticals (INDV) Assets Average (2025 - 2026)
Indivior Pharmaceuticals' (INDV) quarterly Assets Average came in at $1.2 billion in Q1 2026, down 10.89% year-on-year from $1.3 billion in Q1 2025, and down 8.37% quarter-over-quarter from $1.3 billion in Q4 2025.
Indivior Pharmaceuticals (INDV) Assets Average (2025 - 2026) Analysis & Trends
Indivior Pharmaceuticals' Assets Average history runs 2 years deep, the most recent figure standing at $1.2 billion for Q1 2026.
- On a quarterly basis, Assets Average fell 10.89% year-over-year to $1.2 billion in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 10.89% decrease from a year earlier, with the FY2025 full-year figure at $1.3 billion, down 18.12% from the prior year.
- Assets Average declined to $1.2 billion in Q1 2026 per INDV's latest filing, from $1.3 billion in the prior quarter.
- Across five years, Assets Average topped out at $1.4 billion in Q3 2025 and bottomed at $1.2 billion in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 43.72 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 40.39 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 15.32 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 99.52 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 7.30 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 68.63 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 37.01 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 4.77 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 13.29 Bn |
| 10 | Indivior Pharmaceuticals | 1.00 Bn | 829.65 Mn | 277.00 Mn | 1.20 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.20 Bn |
| Dec 31, 2025 | 1.31 Bn |
| Sep 30, 2025 | 1.43 Bn |
| Jun 30, 2025 | 1.41 Bn |
| Mar 31, 2025 | 1.35 Bn |